Lista de obras -

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis

artículo científico publicado en 2020

Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab

scientific article published on 19 March 2019

Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study Health Study

scientific article published on 30 January 2020

Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial

artículo científico publicado en 2018

Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages

artículo científico publicado en 2018

Favorable effect of sodium-glucose co-transporter-2 inhibitor dapagliflozin on nonalcoholic fatty liver disease compared with pioglitazone

artículo científico publicado en 2020

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial

scientific article published on 13 October 2019

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin

artículo científico publicado en 2020

Impaired insulin secretion predicting unstable glycemic variability and Time-Below-Range in type 2 diabetes regardless of HbA1c or diabetes treatment

artículo científico publicado en 2020

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial

scientific article published on 19 September 2018

Insulin-Induced Distant Site Lipoatrophy

artículo científico publicado en 2017

Proinsulin is sensitive to reflect glucose intolerance

scientific article published on 13 July 2019

Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes

artículo científico publicado en 2019

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea

artículo científico publicado en 2018

SGLT2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes

scientific article published on 27 June 2020

Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.

artículo científico publicado en 2017

Serum adiponectin and insulin secretion: a direct or inverse association?

artículo científico publicado en 2018

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes

artículo científico publicado en 2018

Lista de obras de

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis

Case of fulminant type 1 diabetes induced by the anti-programmed death-ligand 1 antibody, avelumab

Correlation between serum proinsulin levels and fatty liver: The Dynamics of Lifestyle and Neighborhood Community on Health Study Health Study

Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial

Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages

Favorable effect of sodium-glucose co-transporter-2 inhibitor dapagliflozin on nonalcoholic fatty liver disease compared with pioglitazone

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients type 2 diabetes treated with canagliflozin plus teneligliptin

Impaired insulin secretion predicting unstable glycemic variability and Time-Below-Range in type 2 diabetes regardless of HbA1c or diabetes treatment

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial

Insulin-Induced Distant Site Lipoatrophy

Proinsulin is sensitive to reflect glucose intolerance

Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea

SGLT2 inhibitors reduce day-to-day glucose variability in patients with type 1 diabetes

Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.

Serum adiponectin and insulin secretion: a direct or inverse association?

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes